DBV Technologies (DBV) Q4 2025 earnings summary

Executive summary

• Advanced VIASKIN Peanut Patch clinical programs for peanut-allergic toddlers (1–3 years) and children (4–7 years), reporting positive Phase 3 VITESSE trial results for ages 4–7.

• Strengthened executive team with key appointments to support BLA submission and potential U.S. launch.

• Maintained active engagement with scientific and patient communities through major allergy congresses.

Financial highlights

• Operating income for 2025 was $5.6 million, up from $4.2 million in 2024, driven by higher French Research Tax Credit activities.

• Net loss for 2025 was $147.0 million, compared to $113.9 million in 2024; net loss per share was $1.05 versus $1.17.

• R&D expenses rose by $27.3 million year-over-year, mainly due to pre-commercial inventory, clinical expenses, and increased staffing.

• SG&A expenses increased by $4.6 million, primarily from market research and operational expansion for launch readiness.

• Cash and cash equivalents were $194.2 million at year-end 2025, with an additional $94 million received in January 2026.

Outlook and guidance

• BLA submission for ages 4–7 expected in H1 2026, with potential for Priority Review.

• Completion of COMFORT Toddlers study enrollment and topline results anticipated.

• BLA submission for ages 1–3 planned for H2 2026 under Accelerated Approval Pathway.

• Cash runway projected into Q2 2027 based on current operations and financing.